Valeant may think Allergan is a great buyout fit, as evidenced by the $47 billion bid it made for the California company Tuesday. But Allergan may feel differently–at least at the current offering price.
written on 23.04.2014
Allergan poison pill presages a battle against Valeant's $47B takeover
